S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
TD Cowen has maintained a Buy rating on shares of Metagenomi Inc (NASDAQ: MGX), following the release of encouraging data from the company's gene editing program for hemophilia A.
The latest 12-month non-human primate (NHP) data showed that Factor VIII (FVIII) activity levels remained durable, demonstrating 9%, 41%, and 82% of normal activity levels without significant decline between the 9-12 month and 3-6 month periods.
The ongoing research into Metagenomi's hemophilia A treatment indicates that the therapy is tolerable and has not resulted in any notable adverse events (AEs). The findings are consistent with earlier data presented at the 4.5-month mark, suggesting stability in the therapy's performance over time.
Metagenomi's development candidate, MGX-001, is anticipated to continue progressing as planned, with its Investigational New Drug (IND) application expected to be submitted by the year 2026.
The company's efforts are directed towards advancing this potential treatment for hemophilia A, a genetic disorder that impairs blood clotting.
The positive data from the NHP study supports the company's approach to gene editing and its application in treating hemophilia A. The durability and tolerability of the therapy at this stage are critical indicators of its potential effectiveness and safety profile for future human clinical trials.
In other recent news, Metagenomi, a genetic medicines company, has reported progress in a preclinical study for their investigational therapy MGX-001 for hemophilia A, showing sustained efficacy over twelve months in nonhuman primates.
The study results suggested the treatment was generally well tolerated, with no significant decline in Factor VIII activity levels, essential for blood clotting. Metagenomi aims to establish a durable, one-time curative treatment for hemophilia A, and is on track for an Investigational New Drug filing in 2026.
However, H.C. Wainwright recently lowered its price target on Metagenomi shares in response to potential increased competition from Pfizer (NYSE:PFE)'s successful Phase 3 gene therapy trial for Hemophilia A. Despite this, H.C. Wainwright maintained a Buy rating on Metagenomi, highlighting its strong Hemophilia A program and sufficient capital to fund operations until 2027.
In contrast, JPMorgan downgraded Metagenomi from Overweight to Neutral, following the termination of the company's partnership with Moderna (NASDAQ:MRNA). Despite the downgrade, JPMorgan does not foresee an immediate impact on Metagenomi's ongoing partnership with Ionis or near-term catalysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.